



Please type a plus sign (+) inside this box → ☐

Guidant Disclosure No.: 1800, 2017

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3763
#5
Prior Art
Buyer
8/8/01

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/749,144
	Filing Date	12/27/2000
	First Named Inventor	ROORDA, WOUTER
	Group Art Unit	3763
	Examiner Name	Not yet assigned
Total Number of Pages in This Submission	Attorney Docket Number	3764.P142

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) (3 Pages)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Postcard (2) & Cited References (59)
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Please charge any insufficiencies, if any, to Deposit Account Number 02-2666.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	William F. Ryann, Reg. No., 44,313	Blakely Sokoloff Taylor & Zafman 12400 Wilshire Boulevard Seventh Floor Los Angeles, CA 90025-1026
Signature	<i>William F. Ryann</i>	
Date	7/31/01	

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <u>7/31/2001</u>			
Typed or printed name	June Y. Criner		
Signature	<i>June Y. Criner</i>	Date	7/31/2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) in this box

+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number~~



Substitute for form 1449A/PTO

(modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

5

Complete if known

Application Number

09/749,144

Filing Date

12/27/2000

First Named Inventor

ROORDA, WOUTER

Group Art Unit

3763

Examiner Name

Not Yet Assigned

Attorney Docket Number

03764.P142

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		4,708,718		Daniels	11/24/1987	
		5,151,100		Abele et al.	9/29/1992	
		5,180,366		Woods	1/19/1993	
		5,356,388		Sepetka et al.	10/18/1994	
		5,380,307		Chee et al.	1/10/1995	
		5,380,747		Medford et al.	1/10/1995	
		5,462,523		Samson et al.	10/31/1995	
		5,496,311		Abele et al.	3/5/1996	
		5,538,504		Linden et al.	7/23/1996	
		5,569,197		Helmus et al.	10/29/1996	
		5,588,962		Nicholas et al.	12/31/1996	
		5,652,059		Margel	7/29/1997	
		5,770,222		Unger et al.	6/23/1998	

RECEIVED
AUG -7 2001
TC 3700 MAIL ROOM

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Office ³	Foreign Patent Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶

Examiner Signature	Date Considered
-----------------------	--------------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See Attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) in this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-P10 (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	09/749,144
				Filing Date	12/27/2000
				First Named Inventor	ROORDA, WOUTER
				Group Art Unit	3763
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	03764.P142
Sheet	2	of	5		

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		5,792,094		Stevens et al.	8/11/1998	
		5,795,318		Wang et al.	8/18/1998	
		5,797,870		March et al.	8/25/1998	
		5,843,051		Adams et al.	12/1/1998	
		5,866,561		Ungs	2/2/1999	
		5,893,840		Hull et al.	4/13/1999	
		5,954,706		Sahatjian	9/21/1999	

RECORDED
AUG - 7 2001
TC 3700 MAIL ROOM

RECEIVED
AUG - 7 2001
TC 3700 MAIL ROOM

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Office ³	Foreign Patent Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Guidant Disclosure Number: 1800, 201

PTO/SB/08A (08-00)

Please type a plus sign (+) in this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/RWD (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	09/749,144
				Filing Date	12/27/2000
				First Named Inventor	ROORDA, WOUTER
				Group Art Unit	3763
				Examiner Name	Not Assigned
Sheet	3	of	5	Attorney Docket Number	03764.P142


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		RAHIMTOOLA S. "The Hibernating Myocardium", Am. Heart Journal, 1989, pgs 211-221, Vol. 117, No. 1.	
		CHILIAN W. et al., "Microvascular Occlusions Promote Coronary Collateral Growth", Am. J Physiol, 1990, pgs H1103-11.	
		SCHAPER W., "Angiogenesis In The Adult Heart" Basic Res Cardiol, 1991, pgs 51-56, Vol 86 Suppl.	
		RIESEN R. et al., "Prospects for Site-Specific Delivery of Pharmacologic and Molecular Therapies" JACC, April 1994, pgs 1234-44, Vol. 23, No. 5.	
		KERSTEN J. et al., "Modulation of Coronary Collateral Angiogenesis: A Canine Model of Neovascularization Induced by Chronic Ischemia", J Card Surg, 1995, pgs 354-7, Vol. 10.	
		SCHAPER W. et al., "Molecular Mechanisms of Coronary Collateral Vessel Growth", Circulation Research, November 1996, pgs 911-919, Vol. 79, No. 5.	
		BRIEGER D. et al., "Local Drug Delivery Systems And Prevention Of Restenosis", Cardiovascular Research, 1997, pgs 405-413, Vol. 35.	
		ITO W. et al., "Angiogenesis But Not Collateral Growth is Associated With Ischemia After Femoral Artery Occlusion", Am. J. Physiol., 1997, pgs. H1255-1265, Vol. 273.	
		TYAGI S., "Vasculogenesis and Angiogenesis: Extracellular Matrix Remodeling in Coronary Collateral Arteries in the Ischemic Heart", Journal of Cellular Biochemistry, 1997, pgs 388-394, Vol. 65.	
		SAUNDERS M. et al., "Release of Granulocyte-Macrophage Colony Stimulating Factor by Human Cultured Airway Smooth Muscle Cells: Suppression by Dexamethasone", Br J Pharmacol, Feb 1997, pgs 545-546, Vol. 120, No. 4.	
		ITO W. et al., "Monocyte Chemotactic Protein-1 Increases Collateral and Peripheral Conductance After Femoral Artery Occlusion", Circ Res, June 1997, pgs 829-837, Vol. 80, No. 6.	
		WEIHRAUCH D. et al. "Repetitive Coronary Artery Occlusions Induce Release of Growth Factors into the Myocardial Interstitium", Am. J. Physiol, 1998, pgs H969-76.	
		WOLF C. et al., "Vascular Remodeling and Altered Protein Expression During Growth of Coronary Collateral Arteries", J Mol. Cell. Cardiol., 1998, pgs 2291-2305, Vol. 30, Academic Press.	
		ARRAS M. et al., "Monocyte Activation in Angiogenesis and Collateral Growth in the Rabbit Hindlimb", Journal of Clinical Investigation, Jan 1, 1998, pgs 40-50, Vol 101, No. 1.	
		ITO W. et al., "Collateral Artery Growth" Local Drug Delivery Meeting and Cardiovascular Course on Radiation & Molecular Strategies, Feb 26-28, 1998, Geneva, Switzerland.	
		DEINDL E. et al., "VEGF, An Important Angiogenic Factor is Not Involved in Arteriogenesis" Journal of Molecular Medicine, May 1998, pgs. B24, P-85.	
		DEINDL E. et al., "Arteriogenesis Is Not Mediated By VEGF", Journal of Molecular and Cellular Cardiology, June 1998, pgs A127, #497, Vol 30, No. 6.	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Grant Disclosure Number: 1800, 20

PTO/SB/08A (08-00)

Please type a plus sign (+) in this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449 (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	09/749,144
				Filing Date	12/27/2000
				First Named Inventor	ROORDA, WOUTER
				Group Art Unit	3763
				Examiner Name	Not Assigned
Sheet	4	of	5	Attorney Docket Number	03764.P142

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GOURDIE R. et al., "Endothelin-Induced Conversion of Embryonic Heart Muscle Cells Into Impulse-Conducting Purkinje Fibers", Proc Natl Acad Sci USA, June 9, 1998, pgs 6815-6818, Vol. 95, No. 12.	
		HOFFER I. et al., "MCP-1 Increases the Number of Collaterals and Capillaries in the Rabbit Hindlimb", Journal of Molecular and Cellular Cardiology, June 1998, pgs A126, #495, Vol. 30, No. 6.	
		TEREB D. et al., "In Vivo Model for Coronary Artery Studies", Journal of Molecular and Cellular Cardiology, June 1998, pgs A42, #157, Vol. 30, No. 6.	
		SCHEINOWITZ M. et al., "Fragmin Does Not Affect Left Ventricular Perfusion And Function Following Acute MI in Swine", Journal of Molecular and Cellular Cardiology, June 1998, pgs A42, #158, Vol. 30, No. 6.	
		VOSSCHULTE R. et al., "Extracellular Proteolysis is Essential For Coronary Arteriogenesis", Journal of Molecular and Cellular Cardiology, June 1998, pgs A42, #159, Vol. 30, No. 6.	
		TSUJIMURA S. et al., "Enhanced Expression of VEGF mRNA And Angiogenic Activity After Acute Myocardial Infarction (AMI) in Rats", Journal of Molecular and Cellular Cardiology, June 1998, pgs A42, #160, Vol. 30, No. 6.	
		IWAKURA A. et al., "Coronary Stenosis and Mechanisms of Collateral Vessel Growth" Nippon Rinsho, Oct 1999, pgs 2504-2508, Vol. 56, No. 10.	
		INOUE M. et al., "Vascular Endothelial Growth Factor (VEGF) Expression in Human Coronary Atherosclerotic Lesions: Possible Pathophysiological Significance of VEGF in Progression of Atherosclerosis", Circulation, Nov 1998, pgs 2108-2116, Vol. 98, No. 20.	
		BUSCHMANN I. et al., "Attraction of Loaded Monocytes Via MCP-1: A Novel Strategy For Therapeutic Arteriogenesis", Oral Presentations: Max Planck Institute, Dept. for Experimental Cardiology, 1999.	
		www.naturalbypass.com , Vasomedical, Inc., Dec 3, 1999.	
		SORAN O. et al., "Enhanced External Counterpulsation in the Management of patients with Cardiovascular Disease", Clin Cardiol, 1999, pgs 173-8, Vol. 22.	
		VOELCKEL W. et al., "Effect of small dose dopamine on mesenteric blood flow and renal function in a pig model of cardiopulmonary resuscitation with vasopressin", Anesth Analg, 1999, pgs 1430-6, Vol. 89.	
		MACRIS M. et al., "Minimally Invasive Access of the Normal Pericardium: Initial Clinical Experience With a Novel Device", Clin Cardiol, Jan 1999, pgs 136-139, Vol. 1 Suppl 1.	
		FLEISCH M. et al., "Direct Relation Between Quantitatively Determined Coronary Collateral Flow and Intracoronary Basic Fibroblast Growth Factor Concentration", Oral Presentation: Session - Basic Aspects of Gene Therapy and Angiogenesis, Morial Convention Center, Room 222, March 9, 1999, Abstract 826-5.	
		GIBSON M. et al., "Magnitude and Location of New Angiographically Apparent Coronary Collaterals Following Intravenous VEGF Administration", Oral Presentation: Session - Intractable Angina: Trials of Vascular Growth Factors, Morial Convention Center, Room 345, March 10, 1999, Abstract 874-5.	
		ISNER J. et al., "Angiogenesis and Vasculogenesis as Therapeutic Strategies for Postnatal Neovascularization", The Journal of Clinical Investigation, May 1999, pgs 1231-1236, Vol. 103, No. 9.	
		BUSCHMANN I. et al., "Arteriogenesis Versus Angiogenesis: Two Mechanisms of Vessel Growth" News Physiol. Sci., June 1999, pgs. 121-125, Vol. 14.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) in this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	09/749,144
				Filing Date	12/27/2000
				First Named Inventor	ROORDA, WOUTER
				Group Art Unit	3763
				Examiner Name	Not Assigned
				Attorney Docket Number	03764.P142
Sheet	5	of	5		

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.